GeoVax Labs Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $4.13 million. The enterprise value is $3.26 million.
| Market Cap | 4.13M |
| Enterprise Value | 3.26M |
Important Dates
The next estimated earnings date is Monday, July 27, 2026, after market close.
| Earnings Date | Jul 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 3.47 million shares outstanding. The number of shares has increased by 342.03% in one year.
| Current Share Class | 3.47M |
| Shares Outstanding | 3.47M |
| Shares Change (YoY) | +342.03% |
| Shares Change (QoQ) | +15.78% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 15.47% |
| Float | 3.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.85 |
| Forward PS | n/a |
| PB Ratio | 6.79 |
| P/TBV Ratio | 8.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.80.
| Current Ratio | 1.06 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -509.28% and return on invested capital (ROIC) is -305.97%.
| Return on Equity (ROE) | -509.28% |
| Return on Assets (ROA) | -194.58% |
| Return on Invested Capital (ROIC) | -305.97% |
| Return on Capital Employed (ROCE) | -3,112.98% |
| Weighted Average Cost of Capital (WACC) | 22.37% |
| Revenue Per Employee | $44,857 |
| Profits Per Employee | -$1.12M |
| Employee Count | 19 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.19% in the last 52 weeks. The beta is 3.68, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.68 |
| 52-Week Price Change | -90.19% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 5.61 |
| Relative Strength Index (RSI) | 39.94 |
| Average Volume (20 Days) | 732,952 |
Short Selling Information
The latest short interest is 271,752, so 7.82% of the outstanding shares have been sold short.
| Short Interest | 271,752 |
| Short Previous Month | 584,471 |
| Short % of Shares Out | 7.82% |
| Short % of Float | 8.49% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, GeoVax Labs had revenue of $852,282 and -$21.37 million in losses. Loss per share was -$15.94.
| Revenue | 852,282 |
| Gross Profit | -15.82M |
| Operating Income | -21.51M |
| Pretax Income | -21.37M |
| Net Income | -21.37M |
| EBITDA | -21.44M |
| EBIT | -21.51M |
| Loss Per Share | -$15.94 |
Balance Sheet
The company has $1.27 million in cash and $394,571 in debt, with a net cash position of $877,191 or $0.25 per share.
| Cash & Cash Equivalents | 1.27M |
| Total Debt | 394,571 |
| Net Cash | 877,191 |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 493,770 |
| Book Value Per Share | 0.18 |
| Working Capital | 139,783 |
Cash Flow
In the last 12 months, operating cash flow was -$19.05 million and capital expenditures -$10,718, giving a free cash flow of -$19.06 million.
| Operating Cash Flow | -19.05M |
| Capital Expenditures | -10,718 |
| Depreciation & Amortization | 63,911 |
| Net Borrowing | n/a |
| Free Cash Flow | -19.06M |
| FCF Per Share | -$5.49 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,523.43% |
| Pretax Margin | -2,507.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -342.03% |
| Shareholder Yield | -342.03% |
| Earnings Yield | -517.01% |
| FCF Yield | -461.07% |
Analyst Forecast
The average price target for GeoVax Labs is $10.00, which is 740.34% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 740.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 12, 2026. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jan 12, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
GeoVax Labs has an Altman Z-Score of -93.67 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -93.67 |
| Piotroski F-Score | 1 |